Skip to content
DataLookout
Menu

ROXI-ATLASNCT07175428

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 25 versions: 25 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 87 → 91 locations
  2. Minor Study sites: 87 to 89
  3. Minor Trial sites expanded: 84 → 87 locations
  4. Minor Trial sites expanded: 81 → 84 locations
  5. Notable Eligibility criteria expanded, about 12 words
    • Trial sites expanded: 77 → 81 locations
  6. Minor Trial sites expanded: 74 → 77 locationsv20
  7. Minor Trial sites expanded: 70 → 74 locationsv19
  8. Minor Trial sites expanded: 59 → 70 locationsv18
  9. Minor Trial sites expanded: 48 → 59 locationsv17
  10. Minor Trial sites expanded: 45 → 48 locationsv16
  11. Minor Study sites revised (45)v15
  12. Notable Eligibility criteria shortened, about 7 words
    • Trial sites expanded: 42 → 45 locations
    v14
  13. Minor Study sites: 41 to 42v13
  14. Minor Trial sites expanded: 37 → 41 locationsv12
  15. Minor Study sites: 34 to 37v11
  16. Minor Study sites: 30 to 34v10
  17. Minor Study sites: 25 to 30v9
  18. Minor Study sites: 21 to 25v8
  19. Minor Study sites: 20 to 21v7
  20. Minor Study sites: 15 to 20v6
  21. Minor Study sites: 13 to 15v5
  22. Minor Study sites: 5 to 13v4
  23. Minor Study sites: 2 to 5v3
  24. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 2
    • Primary completion date: Apr 26, 2027 to Feb 9, 2027
    • Study completion date: Apr 26, 2027 to Apr 21, 2027
    • Start date changed from estimate of Oct 21, 2025 to Oct 20, 2025
  25. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of any bleeding
Timeframe: 12 weeks

Secondary (18)

Incidence of the composite of ISTH major bleeding or ISTH CRNM bleeding
Incidence of ISTH major bleeding
Incidence of ISTH CRNM bleeding
Incidence of minor bleeding
Number of ISTH major bleeding events
Show 13 moreShow less
Number of ISTH CRNM bleeding events
Number of minor bleeding events
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Incidence of the composite of stroke or systemic embolism
Incidence of Antidrug Antibodies (ADA) to REGN7508
Magnitude of ADA to REGN7508
Incidence of ADA to REGN9933
Magnitude of ADA to REGN9933
Concentrations of REGN7508
Concentrations of REGN9933
Change from baseline in activated Partial Thromboplastin Time (aPTT)
Change from baseline in Prothrombin Time (PT)

Arms and interventions

REGN7508Experimental
REGN9933Experimental
ApixabanActive comparator

Drugs: REGN7508, REGN9933, Apixaban

Sites

91 sites in 4 countries

United States 43, Brazil 24, Canada 16, Argentina 8